ID

16954

Description

Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00375791

Link

https://clinicaltrials.gov/show/NCT00375791

Keywords

Versions (2)
  1. 8/16/16 8/16/16 -
  2. 8/16/16 8/16/16 - Julian Varghese
Uploaded on

August 16, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Multiple Myeloma NCT00375791

English

Eligibility Multiple Myeloma NCT00375791

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. plasmacytomas on tissue biopsy.
Description

Criteria 1-3 are major criteria

Data type

boolean

Alias
UMLS CUI [1]
C0032131
2. bone marrow plasmacytosis (> 30% plasma cells).
Description

Bone marrow plasmacytosis

Data type

boolean

Alias
UMLS CUI [1]
C0238803
3. monoclonal immunoglobulin spike on serum electrophoresis immunoglobulin g (igg) > 3.5 g/dl or immunoglobulin a (iga) > 2.0 g/dl; kappa or lambda light chain excretion > 1 g/day on 24 hour urine protein electrophoresis.
Description

monoclonal immunoglobulin spike, IgG, IgA, kappa or lambda light chain excretion on 24 hour urine protein electrophoresis

Data type

boolean

Alias
UMLS CUI [1]
C0860896
UMLS CUI [2]
C0202087
UMLS CUI [3]
C0202083
UMLS CUI [4,1]
C0021036
UMLS CUI [4,2]
C2321676
UMLS CUI [5,1]
C0021037
UMLS CUI [5,2]
C2321676
minor criteria:
Description

Minor criteria

Data type

boolean

Alias
UMLS CUI [1,1]
C1516637
UMLS CUI [1,2]
C0205165
1. bone marrow plasmacytosis (10 to 30% plasma cells)
Description

following criteria 1. -4. are minor criteria

Data type

boolean

Alias
UMLS CUI [1]
C0238803
2. monoclonal immunoglobulin present but of lesser magnitude than given under major criteria
Description

Monoclonal immunoglobulin

Data type

boolean

Alias
UMLS CUI [1]
C0700271
3. lytic bone lesions
Description

Lytic bone lesions

Data type

boolean

Alias
UMLS CUI [1]
C0221204
4. normal immunoglobulin m (igm) < 50 mg/dl, iga < 100 mg/dl or igg < 600 mg/dl.
Description

IgM, IgA, IgG

Data type

boolean

Alias
UMLS CUI [1]
C0202084
UMLS CUI [2]
C0202083
UMLS CUI [3]
C0202087
any of the following sets of criteria will confirm the diagnosis of multiple myeloma:
Description

following sets of criteria will confirm the diagnosis of multiple myeloma

Data type

boolean

Alias
UMLS CUI [1,1]
C0026764
UMLS CUI [1,2]
C0750484
1. any two of the major criteria.
Description

Eligibility Criteria

Data type

boolean

Alias
UMLS CUI [1]
C1516637
2. major criterion 1 plus minor criterion b, c or d.
Description

Eligibility Criteria

Data type

boolean

Alias
UMLS CUI [1]
C1516637
3. major criterion 3 plus minor criterion a or c.
Description

Eligibility Criteria

Data type

boolean

Alias
UMLS CUI [1]
C1516637
4. minor criteria a, b and c or a, b and d.
Description

Eligibility Criteria

Data type

boolean

Alias
UMLS CUI [1]
C1516637
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. renal insufficiency (serum creatinine levels > 3 mg/dl).
Description

Renal insufficiency

Data type

boolean

Alias
UMLS CUI [1]
C0201976
2. patients who present with either alt or ast ≥ 2.5 x upper limit of normal.
Description

ALT/AST

Data type

boolean

Alias
UMLS CUI [1]
C0201836
UMLS CUI [2]
C0201899
3. history of allergic reactions attributed to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine).
Description

Hypersensitivity to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine)

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0754570
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0068006
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0044549
4. concomitant therapy medications that include corticosteroids (except as indicated for other medical conditions, or up to 100 mgs of hydrocortisone as premedication for administration of certain medications or blood products) or other chemotherapy that is or may be active against myeloma, or therapy with chemotherapy within 3 weeks prior to day 1. nitrosoureas must be discontinued 6 weeks prior to day 1.
Description

Corticosteroids, other chemotherapy, nitrosoureas

Data type

boolean

Alias
UMLS CUI [1]
C0038317
UMLS CUI [2]
C0392920
UMLS CUI [3]
C0028210
5. subjects with a hemoglobin < 8.0 g/dl.
Description

Hb

Data type

boolean

Alias
UMLS CUI [1]
C0518015
6. any condition, including laboratory abnormalities, that in the opinion of the investigator, places the subject at unacceptable risk if he/she were to participate in the study.
Description

Any condition that places the subject at unacceptable risk if they were to participate in the study

Data type

boolean

Alias
UMLS CUI [1,1]
C1321605
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488
7. women of childbearing potential (wcbp) who are pregnant, or breast-feeding or men and women who are not using adequate contraception are excluded.
Description

Pregnant or breast feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3]
C0700589
8. plasma cell leukemia.
Description

Plasma cell leukemia

Data type

boolean

Alias
UMLS CUI [1]
C0023484
Back to the top of the page

Similar models

Eligibility Multiple Myeloma NCT00375791

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Plasmacytomas
Item
1. plasmacytomas on tissue biopsy.
boolean
C0032131 (UMLS CUI [1])
Bone marrow plasmacytosis
Item
2. bone marrow plasmacytosis (> 30% plasma cells).
boolean
C0238803 (UMLS CUI [1])
monoclonal immunoglobulin spike, IgG, IgA, kappa or lambda light chain excretion on 24 hour urine protein electrophoresis
Item
3. monoclonal immunoglobulin spike on serum electrophoresis immunoglobulin g (igg) > 3.5 g/dl or immunoglobulin a (iga) > 2.0 g/dl; kappa or lambda light chain excretion > 1 g/day on 24 hour urine protein electrophoresis.
boolean
C0860896 (UMLS CUI [1])
C0202087 (UMLS CUI [2])
C0202083 (UMLS CUI [3])
C0021036 (UMLS CUI [4,1])
C2321676 (UMLS CUI [4,2])
C0021037 (UMLS CUI [5,1])
C2321676 (UMLS CUI [5,2])
Minor criteria
Item
minor criteria:
boolean
C1516637 (UMLS CUI [1,1])
C0205165 (UMLS CUI [1,2])
Bone marrow plasmacytosis
Item
1. bone marrow plasmacytosis (10 to 30% plasma cells)
boolean
C0238803 (UMLS CUI [1])
Monoclonal immunoglobulin
Item
2. monoclonal immunoglobulin present but of lesser magnitude than given under major criteria
boolean
C0700271 (UMLS CUI [1])
Lytic bone lesions
Item
3. lytic bone lesions
boolean
C0221204 (UMLS CUI [1])
IgM, IgA, IgG
Item
4. normal immunoglobulin m (igm) < 50 mg/dl, iga < 100 mg/dl or igg < 600 mg/dl.
boolean
C0202084 (UMLS CUI [1])
C0202083 (UMLS CUI [2])
C0202087 (UMLS CUI [3])
following sets of criteria will confirm the diagnosis of multiple myeloma
Item
any of the following sets of criteria will confirm the diagnosis of multiple myeloma:
boolean
C0026764 (UMLS CUI [1,1])
C0750484 (UMLS CUI [1,2])
Eligibility Criteria
Item
1. any two of the major criteria.
boolean
C1516637 (UMLS CUI [1])
Eligibility Criteria
Item
2. major criterion 1 plus minor criterion b, c or d.
boolean
C1516637 (UMLS CUI [1])
Eligibility Criteria
Item
3. major criterion 3 plus minor criterion a or c.
boolean
C1516637 (UMLS CUI [1])
Eligibility Criteria
Item
4. minor criteria a, b and c or a, b and d.
boolean
C1516637 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Renal insufficiency
Item
1. renal insufficiency (serum creatinine levels > 3 mg/dl).
boolean
C0201976 (UMLS CUI [1])
ALT/AST
Item
2. patients who present with either alt or ast ≥ 2.5 x upper limit of normal.
boolean
C0201836 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
Hypersensitivity to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine)
Item
3. history of allergic reactions attributed to compounds of similar chemical or biologic composition to perifosine (miltefosine or edelfosine).
boolean
C0020517 (UMLS CUI [1,1])
C0754570 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0068006 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0044549 (UMLS CUI [3,2])
Corticosteroids, other chemotherapy, nitrosoureas
Item
4. concomitant therapy medications that include corticosteroids (except as indicated for other medical conditions, or up to 100 mgs of hydrocortisone as premedication for administration of certain medications or blood products) or other chemotherapy that is or may be active against myeloma, or therapy with chemotherapy within 3 weeks prior to day 1. nitrosoureas must be discontinued 6 weeks prior to day 1.
boolean
C0038317 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
C0028210 (UMLS CUI [3])
Hb
Item
5. subjects with a hemoglobin < 8.0 g/dl.
boolean
C0518015 (UMLS CUI [1])
Any condition that places the subject at unacceptable risk if they were to participate in the study
Item
6. any condition, including laboratory abnormalities, that in the opinion of the investigator, places the subject at unacceptable risk if he/she were to participate in the study.
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
Pregnant or breast feeding
Item
7. women of childbearing potential (wcbp) who are pregnant, or breast-feeding or men and women who are not using adequate contraception are excluded.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0700589 (UMLS CUI [3])
Plasma cell leukemia
Item
8. plasma cell leukemia.
boolean
C0023484 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial